Advertisement

International Cancer Conference Journal

, Volume 8, Issue 1, pp 33–38 | Cite as

Uterine leiomyosarcoma well-controlled with eribulin mesylate

  • Etsuko FujimotoEmail author
  • Kazuhiro Takehara
  • Tamaki Tanaka
  • Takanori Yokoyama
  • Katsuyuki Tomono
  • Mika Okazawa-Sakai
  • Shinichi Okame
  • Yoshifumi Sugawara
  • Norihiro Teramoto
Case report
  • 15 Downloads

Abstract

Uterine leiomyosarcoma is a rare type of malignant gynecological tumor and has a poor prognosis; therefore, this tumor is often difficult to treat. Some new drugs have been approved during the past several years in Japan and are expected to be efficacious. Eribulin, one of these drugs, is a natural product of halichondrin B, which is isolated from a marine sponge. A recent clinical trial comparing eribulin with dacarbazine to target liposarcoma and leiomyosarcoma indicated that overall survival (OS) was prolonged by treatment with eribulin. We report a case of uterine progressive leiomyosarcoma that responded to eribulin. A 57-year-old woman was suspected of having leiomyosarcoma based on an endometrial biopsy and imaging examinations. Although the tumor grew toward the uterine artery on the right side of the uterine cervix, we performed a total abdominal hysterectomy and bilateral salpingo-oophorectomy to obtain an outcome of no gross residual disease. However, the margin of the right side of the uterine cervix was histologically positive, so leiomyosarcoma stage IIB (pT2bcN0cM0, FIGO2008) was diagnosed. Gemcitabine and docetaxel therapy was administered postoperatively. However, after three cycles, the residual tumor progressed. Other anticancer drugs were administered but were ineffective. We administered eribulin (1.4 mg/m2) as a fourth-line regimen, and the mass decreased by 32% after four cycles. However, the residual tumor continued to grow after eight cycles. The only adverse event associated with eribulin treatment was mild, grade 2 neutropenia. For our patient, eribulin was effective for her recurrent leiomyosarcoma. In selecting chemotherapy, there are currently no fixed guidelines; we should consider the characteristics and adverse events associated with each drug and patient performance status and comorbidities. In this patient, eribulin was associated with few adverse events, an easy route of administration and a good quality of life. Therefore, eribulin is expected to be efficacious for the treatment of gynecologic sarcoma.

Keywords

Eribulin Uterine leiomyosarcoma Quality of life 

Notes

Acknowledgements

I appreciate the suggestions and discussions offered by the authors and manuscript translation and editing performed by the medical staff.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

References

  1. 1.
    Schöffski P, Chawla S, Maki RG et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma. Lancet 387:1629–1637CrossRefGoogle Scholar
  2. 2.
    WHO classification of tumors of Female Reproductive Organs; 2014:139–141Google Scholar
  3. 3.
    Seagle BL, Sobecki-Rausch J, Strohl AE et al (2017) Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol 145:61–70CrossRefGoogle Scholar
  4. 4.
    Omura GA, Major FJ, Blessing JA et al (1983) A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626–632CrossRefGoogle Scholar
  5. 5.
    Look KY, Sandler A, Blessing JA et al (2004) PhaseII trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92:644–647CrossRefGoogle Scholar
  6. 6.
    Sutton GP, Blessing JA, Barrett RJ et al (1992) Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 166:556–559CrossRefGoogle Scholar
  7. 7.
    Sutton G, Blessing JA, Park R et al (1996) Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcoma previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol 87:747–750CrossRefGoogle Scholar
  8. 8.
    Hensley ML, Blessing JA, Mannel R et al (2008) Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine sarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109:329–334CrossRefGoogle Scholar
  9. 9.
    Hensley ML, Blessing JA, Degreest K et al (2008) Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 109:323–328CrossRefGoogle Scholar
  10. 10.
    NCCN guideline 2017: https://www.tri-kobe.org/nccn/guideline/gynecological/english/uterine.pdf (accessed on 1 August 2017)
  11. 11.
    Seddon B, Strauss S, Whelan J et al (2017) Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas(GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 18:1397–1410CrossRefGoogle Scholar
  12. 12.
    NCCN guideline 2015: https://www.tri-kobe.org/nccn/guideline/gynecological/english/uterine.pdf (accessed on 1 September 2015)
  13. 13.
    Van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886CrossRefGoogle Scholar
  14. 14.
    Kawai A, Araki N, Sugiura H et al (2015) Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet 16:406–416CrossRefGoogle Scholar
  15. 15.
    Kawai A, Yonemori K, Takahashi S et al (2017) Systemic therapy for soft tissue sarcoma: Proposals for the optimal use of pazopanib, trabectedin, and eribulin. Adv Ther 34:1556–1571CrossRefGoogle Scholar
  16. 16.
    Kuznetsov G, TenDyke K, Yu MJ et al (2007) Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. [abstract C58]. Proc Am Assoc Cancer Res 48:275Google Scholar
  17. 17.
    Funahashi Y, Okamoto K, Adachi Y et al (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334–1342CrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2018

Authors and Affiliations

  • Etsuko Fujimoto
    • 1
    Email author return OK on get
  • Kazuhiro Takehara
    • 1
  • Tamaki Tanaka
    • 1
  • Takanori Yokoyama
    • 1
  • Katsuyuki Tomono
    • 1
  • Mika Okazawa-Sakai
    • 1
  • Shinichi Okame
    • 1
  • Yoshifumi Sugawara
    • 2
  • Norihiro Teramoto
    • 3
  1. 1.Department of Gynecologic OncologyNational Hospital Organization Shikoku Cancer CenterMatsuyamaJapan
  2. 2.Department of RadiologyNational Hospital Organization Shikoku Cancer CenterMatsuyamaJapan
  3. 3.Department of PathologyNational Hospital Organization Shikoku Cancer CenterMatsuyamaJapan

Personalised recommendations